Immunohistochemistry Market by Product (Antibody, Reagent, Kits, Slide Staining System, Tissue Microarray) Application (Diagnostics (Cancer, Cardiovascular, Diabetes, Autoimmune, Infectious Diseases) & Drug Testing) End User - Global Forecast to 2021

The immunohistochemistry (IHC) market is projected to reach USD 2.12 Billion by 2021, growing at a CAGR of 7.3% during the forecast period of 2016 to 2021. Factors such as the growing prevalence of cancer and rapidly increasing geriatric population across the globe are the primary driving the growth of this market. Other factors driving the IHC market growth include increasing healthcare spending and improving healthcare infrastructure resulting in an increasing number of hospitals and diagnostic laboratories. Several manufacturers in the immunohistochemistry market are relied majorly on launching the new products in order to achieve growth in the immunohistochemistry market. In addition, market players are focusing on acquiring local market players to expand their portfolios and enhance their distribution channels in emerging markets.

The global immunohistochemistry market is segmented based on product, application, end user, and region. Based on product, the immunohistochemistry market is segmented into antibodies, reagents, equipment, and kits. Based on application, the immunohistochemistry market is segmented into diagnostics and drug testing. The diagnostic segment is further divided into cancer, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and nephrological diseases. On the basis of end user, the market is segmented into hospitals & diagnostic laboratories, research institutions, and other end users. This report also provides market information across major regional segments, namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. These regions are further segmented at a country level.

North America is the largest market for immunohistochemistry, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. However, Asia-Pacific possesses lucrative growth potential for the immunohistochemistry market during the forecast period. The economic growth of APAC countries, rising number of chronic diseases, rising standard of living, growing demand for quality medical care, increasing healthcare spending and government initiatives, and rising awareness on the use of immunohistochemistry tests are expected to drive market growth of the Asia-Pacific region during the forecast period.

The global immunohistochemistry market is consolidated at the top with the top five companies accounting for more than half of the global market. The major players in the immunohistochemistry market include F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (U.S.), Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck Millipore (U.S.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abcam plc (U.K.), Cell Signaling Technology, Inc. (U.S.), and Bio SB Inc. (U.S.).
Reasons to Buy the Report
This report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater market share. Firms purchasing this report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for reaping a greater market share.

This report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on product portfolios offered by the top players in the immunohistochemistry market. This report analyzes the immunohistochemistry market by product, application, end user, and region
‧ Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and new product launches in the immunohistochemistry market
‧ Market Development: Comprehensive information on the lucrative emerging markets for immunohistochemistry
‧ Market Diversification: Exhaustive information of new products, growing regions, recent developments, and investments in the immunohistochemistry market
‧ Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and manufacturing capabilities of the leading players in the immunohistochemistry market

TABLE OF CONTENTS

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 20
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 22
1.5 STAKEHOLDERS 22
2 RESEARCH METHODOLOGY 23
2.1 RESEARCH APPROACH 23
2.2 MARKET SIZE ESTIMATION 24
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 26
2.4 MARKET SHARE ESTIMATION 27
2.4.1 SECONDARY SOURCES 27
2.4.1.1 Key data from secondary sources 27
2.4.2 PRIMARY SOURCES 28
2.4.2.1 Key data from primary sources 28
2.4.3 KEY INDUSTRY INSIGHTS 29
2.5 ASSUMPTIONS FOR THE STUDY 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 34
4.1 IMMUNOHISTOCHEMISTRY: MARKET OVERVIEW 34
4.2 IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2016 VS. 2021 34
4.3 GEOGRAPHIC SNAPSHOT OF THE IMMUNOHISTOCHEMISTRY MARKET (2015) 35
4.4 IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC MIX 36
4.5 IMMUNOHISTOCHEMISTRY MARKET: DEVELOPING VS. DEVELOPED COUNTRIES (2016-2021) 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 38
5.2 KEY MARKET DYNAMICS 38
5.2.1 MARKET DRIVERS 39
5.2.1.1 Growing prevalence of cancer 39
5.2.1.2 Rapidly increasing geriatric population 40
5.2.1.3 Rapid technological developments in the IVD industry 41
5.2.1.4 Increasing healthcare spending 41
5.2.2 MARKET RESTRAINTS 42
5.2.2.1 Limited reimbursements 42
5.2.2.2 Implementation of excise duty by the U.S. government 42
5.2.3 MARKET OPPORTUNITIES 43
5.2.3.1 Rapid growth in the emerging markets of APAC and Latin America 43
5.2.3.2 Increasing demand for personalized medicine 44
5.2.4 MARKET CHALLENGE 45
5.2.4.1 Regulatory restrictions 45
6 INDUSTRY INSIGHTS 46
6.1 INTRODUCTION 46
6.2 INDUSTRY TRENDS 46
6.2.1 GROWING CONSOLIDATION OF THE IMMUNOHISTOCHEMISTRY MARKET 47
6.2.2 INCORPORATION OF NANOTECHNOLOGY IN IMMUNOHISTOCHEMISTRY 48
6.2.3 ADOPTION OF MULTIPLEX ARRAYS 48
6.2.4 AUTOMATION IN IMMUNOHISTOCHEMISTRY MARKET 48
6.3 REGULATORY ANALYSIS 49
6.3.1 NORTH AMERICA 50
6.3.2 EUROPE 51
6.3.3 ASIA-PACIFIC 52
7 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT 53
7.1 INTRODUCTION 54
7.2 ANTIBODIES 55
7.2.1 PRIMARY ANTIBODIES 57
7.2.2 SECONDARY ANTIBODIES 58
7.3 EQUIPMENT 60
7.3.1 SLIDE STAINING SYSTEMS 62
7.3.2 TISSUE MICROARRAYS 63
7.3.3 TISSUE PROCESSING SYSTEMS 64
7.3.4 SLIDE SCANNERS 65
7.3.5 OTHER EQUIPMENT 66
7.4 REAGENTS 67
7.4.1 HISTOLOGICAL STAINS 68
7.4.2 BLOCKING SERA AND REAGENTS 70
7.4.3 CHROMOGENIC SUBSTRATES 71
7.4.4 FIXATION REAGENTS 72
7.4.5 STABILIZERS 73
7.4.6 ORGANIC SOLVENTS 74
7.4.7 PROTEOLYTIC ENZYMES 75
7.4.8 DILUENTS 76
7.5 KITS 77
8 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION 78
8.1 INTRODUCTION 79
8.2 DIAGNOSTICS 80
8.2.1 CANCER 81
8.2.2 INFECTIOUS DISEASES 83
8.2.3 CARDIOVASCULAR DISEASE 85
8.2.4 AUTOIMMUNE DISEASES 86
8.2.5 DIABETES MELLITUS 87
8.2.6 NEPHROLOGICAL DISEASES 88
8.3 DRUG TESTING 89
9 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY END USER 90
9.1 INTRODUCTION 91
9.2 HOSPITALS AND DIAGNOSTIC LABORATORIES 92
9.3 RESEARCH INSTITUTES 93
9.4 OTHER END USERS 95
10 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY REGION 96
10.1 INTRODUCTION 97
10.2 NORTH AMERICA 99
10.2.1 U.S. 103
10.2.2 CANADA 106
10.3 EUROPE 110
10.3.1 GERMANY 115
10.3.2 FRANCE 118
10.3.3 U.K. 121
10.3.4 ITALY 125
10.3.5 SPAIN 128
10.3.6 REST OF EUROPE 132
10.4 ASIA-PACIFIC 135
10.4.1 JAPAN 139
10.4.2 CHINA 143
10.4.3 INDIA 146
10.4.4 REST OF ASIA-PACIFIC 150
10.5 REST OF THE WORLD 154
10.5.1 LATIN AMERICA 157
10.5.2 MIDDLE EAST AND AFRICA 161
?
11 COMPETITIVE LANDSCAPE 165
11.1 OVERVIEW 165
11.2 MARKET SHARE ANALYSIS 166
11.3 COMPETITIVE SITUATIONS AND TRENDS 168
11.3.1 PRODUCT LAUNCHES 169
11.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 169
11.3.3 ACQUISITIONS 170
11.3.4 EXPANSIONS 171
12 COMPANY PROFILES 172
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 INTRODUCTION 172
12.2 F. HOFFMANN-LA ROCHE AG 173
12.3 DANAHER CORPORATION 177
12.4 AGILENT TECHNOLOGIES, INC. 182
12.5 THERMO FISHER SCIENTIFIC INC. 187
12.6 MERCK MILLIPORE 190
12.7 BIO-RAD LABORATORIES, INC. 194
12.8 PERKINELMER, INC. 196
12.9 ABCAM PLC 199
12.10 CELL SIGNALING TECHNOLOGY, INC. 202
12.11 BIO SB 205

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
13 APPENDIX 207
13.1 INSIGHTS OF INDUSTRY EXPERTS 207
13.2 DISCUSSION GUIDE 208
13.3 OTHER DEVELOPMENTS 213
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 219
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 221
13.6 AVAILABLE CUSTOMIZATIONS 223
13.7 RELATED REPORTS 224
13.8 AUTHOR DETAILS 225